Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060242 · ClinicalTrials.gov registry record · Phase 2
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
A Phase 2 study of Head and Neck Cancer, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT00060242 is a Phase 2 study of Head and Neck Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 26 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00060242, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Combretastatin A4 phosphate may stop the growth of anaplastic thyroid cancer by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well combretastatin A4 phosphate works in treating patients with advanced recurrent or metastatic anaplastic thyroid cancer.
Conditions Studied
Interventions
- DRUG fosbretabulin disodium
Study Locations (3)
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
Ohio
- Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center - Cleveland
Pennsylvania
- Hillman Cancer Center at University of Pittsburgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2003-02 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060242
The ClinicalTrials.gov registry entry for NCT00060242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which fosbretabulin disodium is the first listed.
NCT00060242 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00060242 about?
NCT00060242 is a clinical study titled "Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer". RATIONALE: Combretastatin A4 phosphate may stop the growth of anaplastic thyroid cancer by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well combretastatin A4 phosphate works in treating patients with advanced recurrent or metastatic anaplastic thyroid cancer.
What is the current status of trial NCT00060242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2003-02. Estimated completion is 2008-01.
What conditions does trial NCT00060242 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT00060242?
The interventions under investigation include: fosbretabulin disodium (DRUG).
Who is sponsoring clinical trial NCT00060242?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00060242 being conducted?
This trial has 3 study locations across Michigan, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.